SCHEMBL4260459

SCHEMBL4260459

O=c1oc(Oc2ccccc2)nc2sc(C3CC3)c(Nc3ccccc3)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 3/20 0.35
▸ PDE10A Q9Y233 4/20 0.32
▸ PTGDR2 Q9Y5Y4 1/20 0.31
▸ ALDH1A1 P00352 4/20 0.31
▸ SMN1; SMN2 Q16637 4/20 0.31
▸ MAPT P10636 3/20 0.31
▸ MEN1 O00255 2/20 0.31
▸ KMT2A Q03164 2/20 0.31
▸ HPGD P15428 1/20 0.31
▸ NFKB1 P19838 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ NFKB2 Q00653 1/20 0.31
▸ RELA Q04206 1/20 0.31
▸ AKR1C3 P42330 1/20 0.31
▸ PLA2G1B P04054 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ CASP3 P42574 1/20 0.31
▸ BLM P54132 1/20 0.31
▸ CASP6 P55212 1/20 0.31
▸ CASP8 Q14790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4262183 0.69 ALDH1A1 (0.59) ELANEALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4260456 0.65 ELANE (0.43) ELANEPDE10AALDH1A1SMN1; SMN2HPGD
SCHEMBL4271777 0.65 ALDH1A1 (0.56) ELANEALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4259287 0.61 MAPT (0.54) ELANEALDH1A1MAPTMEN1KMT2A
SCHEMBL10489879 0.61 ELANE (0.69) ELANE
SCHEMBL2077629 0.60 ELANE (0.62) ELANEALDH1A1SMN1; SMN2MAPTKMT2A
SCHEMBL10489786 0.60 ELANE (0.68) ELANE
SCHEMBL10489824 0.60 ELANE (0.47) ELANE
SCHEMBL10489807 0.59 ELANE (0.59) ELANE
SCHEMBL10489922 0.58 ELANE (0.71) ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1446125-B1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LTD (GB) 2009-04-29 — — EP claimed
US-20090029978-A1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY ALIZYME THERAPEUTICS LIMITED (GB) 2009-01-29 — — US claimed
US-7407954-B2 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity ALIZYME THERAPEUTICS LIMITED (GB) 2008-08-05 — — US claimed
US-20050075336-A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity NORGINE B.V. (NL) 2005-04-07 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075336-A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity LPL, LIPE, LIPC ELANE 282/4885PDE10A 1776/4885PTGDR2 400/4885
US-20090029978-A1 THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY LPL, LIPE, LIPC ELANE 282/4885PDE10A 1776/4885PTGDR2 400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback